{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:22:51Z","timestamp":1785280971795,"version":"3.55.0"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The 7th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Renal, and Glycemic Outcomes, was held virtually on November 18\u201319, 2021. Pursuing the tradition of the previous summits, this reference congress served as a platform for in-depth discussion and exchange on recently completed CVOTs. This year\u2019s focus was placed on the outcomes of EMPEROR-Preserved, FIGARO-DKD, AMPLITUDE-O, SURPASS 1\u20135, and STEP 1\u20135. Trial implications for diabetes and obesity management and the impact on new treatment algorithms were highlighted for endocrinologists, diabetologists, cardiologists, nephrologists, and general practitioners. Discussions evolved from outcome trials using SGLT2 inhibitors as therapy for heart failure, to CVOTs with nonsteroidal mineralocorticoid receptor antagonists and GLP-1 receptor agonists. Furthermore, trials for glycemic and overweight\/obesity management, challenges in diabetes management in COVID-19, and novel guidelines and treatment strategies were discussed.<\/jats:p><jats:p><jats:italic>Trial registration<\/jats:italic>The 8th Cardiovascular Outcome Trial Summit will be held virtually on November 10\u201311, 2022 (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.cvot.org\">http:\/\/www.cvot.org<\/jats:ext-link>)<\/jats:p>","DOI":"10.1186\/s12933-022-01481-0","type":"journal-article","created":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T12:02:58Z","timestamp":1649419378000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes"],"prefix":"10.1186","volume":"21","author":[{"given":"Oliver","family":"Schnell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadej","family":"Battelino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Bergenstal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Bl\u00fcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Brosius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ceriello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Forst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Giorgino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Guerci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiddo J. L.","family":"Heerspink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baruch","family":"Itzhak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Kosiborod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neboj\u0161a","family":"Lali\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lehrke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Nauck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena W.","family":"Rodbard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe M. C.","family":"Rosano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Ryd\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Santilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra-Maria","family":"Schumm-Draeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per Olav","family":"Vandvik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Vilsb\u00f8ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Wysham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eberhard","family":"Standl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,8]]},"reference":[{"key":"1481_CR1","unstructured":"International Diabetes Federation. IDF diabetes atlas, 10th edn. Brussels, Belgium. 2021. https:\/\/www.diabetesatlas.org. Accessed 22 Feb 2022."},{"key":"1481_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2021","unstructured":"Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2021;183: 109119.","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"1481_CR3","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1159\/000480525","volume":"10","author":"DR Leitner","year":"2017","unstructured":"Leitner DR, Fr\u00fchbeck G, Yumuk V, Schindler K, Micic D, Woodward E, et al. Obesity and type 2 diabetes: two diseases with a need for combined treatment strategies\u2014EASO can lead the way. Obes Facts. 2017;10(5):483\u201392.","journal-title":"Obes Facts"},{"issue":"4","key":"1481_CR4","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/j.1751-7176.2011.00434.x","volume":"13","author":"AN Long","year":"2011","unstructured":"Long AN, Dagogo-Jack S. Comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection. J Clin Hypertens. 2011;13(4):244\u201351.","journal-title":"J Clin Hypertens"},{"issue":"1","key":"1481_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","volume":"17","author":"TR Einarson","year":"2018","unstructured":"Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007\u20132017. Cardiovasc Diabetol. 2018;17(1):83.","journal-title":"Cardiovasc Diabetol"},{"issue":"9733","key":"1481_CR6","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","volume":"375","author":"N Sarwar","year":"2010","unstructured":"Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Emerging Risk Factors C, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215\u201322.","journal-title":"Lancet"},{"key":"1481_CR7","unstructured":"Schmidt C, Reitzle L, Paprott R, B\u00e4tzing J, Holstiege J. Diabetes mellitus and comorbidities\u2014a cross-sectional study with control group based on nationwide ambulatory claims data. 2021(2):19\u201335."},{"key":"1481_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/B978-0-444-53480-4.00001-1","volume":"126","author":"D Ziegler","year":"2014","unstructured":"Ziegler D, Papanas N, Vinik AI, Shaw JE. Epidemiology of polyneuropathy in diabetes and prediabetes. Handb Clin Neurol. 2014;126:3\u201322.","journal-title":"Handb Clin Neurol"},{"issue":"12","key":"1481_CR9","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2215\/CJN.11491116","volume":"12","author":"RZ Alicic","year":"2017","unstructured":"Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032\u201345.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"1481_CR10","first-page":"S1","volume":"44","author":"American Diabetes Association","year":"2021","unstructured":"American Diabetes Association. Standards of medical care in diabetes\u20142021. Diabetes Care. 2021;44(1):S1\u2013232.","journal-title":"Diabetes Care"},{"issue":"2","key":"1481_CR11","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.kint.2017.01.030","volume":"92","author":"CP Wen","year":"2017","unstructured":"Wen CP, Chang CH, Tsai MK, Lee JH, Lu PJ, Tsai SP, et al. Diabetes with early kidney involvement may shorten life expectancy by 16 years. Kidney Int. 2017;92(2):388\u201396.","journal-title":"Kidney Int"},{"issue":"4","key":"1481_CR12","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2337\/cd16-0005","volume":"34","author":"EE Regier","year":"2016","unstructured":"Regier EE, Venkat MV, Close KL. More than 7 years of hindsight: revisiting the FDA\u2019s 2008 guidance on cardiovascular outcomes trials for type 2 diabetes medications. Clin Diabetes. 2016;34(4):173\u201380.","journal-title":"Clin Diabetes"},{"key":"1481_CR13","unstructured":"U.S. Food and Drug Administration. Guidance for industry diabetes mellitus\u2014evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008. https:\/\/www.fda.gov\/media\/71297\/download. Accessed 22 Feb 2022."},{"issue":"14","key":"1481_CR14","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317\u201326.","journal-title":"N Engl J Med"},{"issue":"3","key":"1481_CR15","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"373","author":"JB Green","year":"2015","unstructured":"Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232\u201342.","journal-title":"N Engl J Med"},{"issue":"14","key":"1481_CR16","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"369","author":"WB White","year":"2013","unstructured":"White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327\u201335.","journal-title":"N Engl J Med"},{"issue":"1","key":"1481_CR17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jama.2018.18269","volume":"321","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321(1):69\u201379.","journal-title":"JAMA"},{"issue":"12","key":"1481_CR18","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1001\/jama.2019.13772","volume":"322","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA. 2019;322(12):1155\u201366.","journal-title":"JAMA"},{"issue":"7","key":"1481_CR19","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"4","key":"1481_CR20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"22","key":"1481_CR21","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"15","key":"1481_CR22","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425\u201335.","journal-title":"N Engl J Med"},{"key":"1481_CR23","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","volume":"384","author":"DL Bhatt","year":"2020","unstructured":"Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2020;384:129\u201339.","journal-title":"N Engl J Med"},{"issue":"24","key":"1481_CR24","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"key":"1481_CR25","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436\u201346.","journal-title":"N Engl J Med"},{"issue":"21","key":"1481_CR26","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"key":"1481_CR27","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413\u201324.","journal-title":"N Engl J Med"},{"key":"1481_CR28","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2020","unstructured":"Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2020;384:117\u201328.","journal-title":"N Engl J Med"},{"issue":"10157","key":"1481_CR29","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S, D\u2019Agostino RB Sr, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519\u201329.","journal-title":"Lancet"},{"issue":"13","key":"1481_CR30","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228\u201339.","journal-title":"N Engl J Med"},{"issue":"4","key":"1481_CR31","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"23","key":"1481_CR32","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kober LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247\u201357.","journal-title":"N Engl J Med"},{"issue":"19","key":"1481_CR33","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"key":"1481_CR34","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219\u201329.","journal-title":"N Engl J Med"},{"issue":"10","key":"1481_CR35","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","volume":"385","author":"HC Gerstein","year":"2021","unstructured":"Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021;385(10):896\u2013907.","journal-title":"N Engl J Med"},{"issue":"24","key":"1481_CR36","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252\u201363.","journal-title":"N Engl J Med"},{"issue":"16","key":"1481_CR37","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"issue":"10295","key":"1481_CR38","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","volume":"398","author":"J Rosenstock","year":"2021","unstructured":"Rosenstock J, Wysham C, Fr\u00edas JP, Kaneko S, Lee CJ, Fern\u00e1ndez Land\u00f3 L, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143\u201355.","journal-title":"Lancet"},{"issue":"6","key":"1481_CR39","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, P\u00e9rez Manghi FC, Fern\u00e1ndez Land\u00f3 L, Bergman BK, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503\u201315.","journal-title":"N Engl J Med"},{"issue":"10300","key":"1481_CR40","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","volume":"398","author":"B Ludvik","year":"2021","unstructured":"Ludvik B, Giorgino F, J\u00f3dar E, Frias JP, Fern\u00e1ndez Land\u00f3 L, Brown K, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398(10300):583\u201398.","journal-title":"Lancet"},{"issue":"10313","key":"1481_CR41","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","volume":"398","author":"S Del Prato","year":"2021","unstructured":"Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811\u201324.","journal-title":"Lancet"},{"issue":"6","key":"1481_CR42","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1001\/jama.2022.0078","volume":"327","author":"D Dahl","year":"2022","unstructured":"Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022;327(6):534\u201345.","journal-title":"JAMA"},{"issue":"11","key":"1481_CR43","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002.","journal-title":"N Engl J Med"},{"issue":"10278","key":"1481_CR44","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies M, F\u00e6rch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971\u201384.","journal-title":"Lancet"},{"issue":"14","key":"1481_CR45","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403\u201313.","journal-title":"JAMA"},{"issue":"14","key":"1481_CR46","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414\u201325.","journal-title":"JAMA"},{"issue":"1","key":"1481_CR47","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12933-020-01022-7","volume":"19","author":"O Schnell","year":"2020","unstructured":"Schnell O, Standl E, Cos X, Heerspink HJL, Itzhak B, Lalic N, et al. Report from the 5th cardiovascular outcome trial (CVOT) summit. Cardiovasc Diabetol. 2020;19(1):47.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1481_CR48","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12933-019-0822-4","volume":"18","author":"O Schnell","year":"2019","unstructured":"Schnell O, Standl E, Catrinoiu D, Itzhak B, Lalic N, Rahelic D, et al. Report from the 4th cardiovascular outcome trial (CVOT) summit of the diabetes & cardiovascular disease (D&CVD) EASD study group. Cardiovasc Diabetol. 2019;18(1):30.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1481_CR49","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12933-018-0667-2","volume":"17","author":"O Schnell","year":"2018","unstructured":"Schnell O, Standl E, Catrinoiu D, Genovese S, Lalic N, Lalic K, et al. Report from the 3rd cardiovascular outcome trial (CVOT) summit of the diabetes & cardiovascular disease (D&CVD) EASD study group. Cardiovasc Diabetol. 2018;17(1):30.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1481_CR50","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12933-017-0508-8","volume":"16","author":"O Schnell","year":"2017","unstructured":"Schnell O, Standl E, Catrinoiu D, Genovese S, Lalic N, Skra J, et al. Report from the 2nd cardiovascular outcome trial (CVOT) summit of the diabetes and cardiovascular disease (D&CVD) EASD study group. Cardiovasc Diabetol. 2017;16(1):35.","journal-title":"Cardiovasc Diabetol"},{"key":"1481_CR51","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12933-016-0357-x","volume":"15","author":"O Schnell","year":"2016","unstructured":"Schnell O, Standl E, Catrinoiu D, Genovese S, Lalic N, Skra J, et al. Report from the 1st cardiovascular outcome trial (CVOT) summit of the diabetes & cardiovascular disease (D&CVD) EASD study group. Cardiovasc Diabetol. 2016;15:33.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1481_CR52","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12933-021-01254-1","volume":"20","author":"O Schnell","year":"2021","unstructured":"Schnell O, Cos X, Cosentino F, Forst T, Giorgino F, Heersprink HJL, et al. Report from the CVOT summit 2020: new cardiovascular and renal outcomes. Cardiovasc Diabetol. 2021;20(1):75.","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"1481_CR53","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1002\/ejhf.1596","volume":"21","author":"SD Anker","year":"2019","unstructured":"Anker SD, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, et al. Evaluation of the effects of sodium\u2013glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-preserved trial. Eur J Heart Fail. 2019;21(10):1279\u201387.","journal-title":"Eur J Heart Fail"},{"key":"1481_CR54","unstructured":"Study to evaluate the efficacy (effect on disease) and safety of finerenone on morbidity (events indicating disease worsening) & mortality (death rate) in participants with heart failure and left ventricular ejection fraction (proportion of blood expelled per heart stroke) greater or equal to 40% (FINEARTS-HF). https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04435626?term=finerenone+heart+failure&draw=2&rank=1. Accessed 07 Mar 2022."},{"key":"1481_CR55","unstructured":"A trial to learn how well finerenone works and how safe it is in adult participants with non-diabetic chronic kidney disease (FIND-CKD). https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05047263?term=finerenone+Non-diabetic+CKD&draw=2&rank=1. Accessed 07 Mar 2022."},{"issue":"1","key":"1481_CR56","first-page":"143","volume":"12","author":"T Min","year":"2021","unstructured":"Min T, Bain SC. The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials. Diabetes Ther Res Treat Educ Diabetes Relat Disord. 2021;12(1):143\u201357.","journal-title":"Diabetes Ther Res Treat Educ Diabetes Relat Disord"},{"key":"1481_CR57","unstructured":"A study of tirzepatide (LY3298176) versus insulin lispro (U100) in participants with type 2 diabetes inadequately controlled on insulin glargine (U100) with or without metformin (SURPASS-6). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04537923. Accessed 22 Feb 2022."},{"key":"1481_CR58","unstructured":"Garvey TW, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al. Two-year effect of semaglutide 2.4 mg vs placebo in adults with overweight or obesity: STEP 5. In: 9th annual meeting of the obesity society (TOS) held at ObesityWeek\u00ae, virtual meeting, November 1\u20135, 2021. https:\/\/sciencehub.novonordisk.com\/content\/dam\/hcpexperience\/kol\/en\/congresses\/ow\/2021\/ow21-step-5-primary-lb\/pdfs\/PPT_Garvey_Two_year_effect_semaglutide_2.4mg_STEP_5_no%20animations.pdf. Accessed 07 Feb 2022."},{"issue":"36","key":"1481_CR59","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021;42(36):3599\u2013726.","journal-title":"Eur Heart J"},{"issue":"6","key":"1481_CR60","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/ejhf.2206","volume":"23","author":"GMC Rosano","year":"2021","unstructured":"Rosano GMC, Moura B, Metra M, B\u00f6hm M, Bauersachs J, Ben Gal T, et al. Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2021;23(6):872\u201381.","journal-title":"Eur J Heart Fail"},{"key":"1481_CR61","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jclinepi.2017.08.009","volume":"91","author":"EA Akl","year":"2017","unstructured":"Akl EA, Meerpohl JJ, Elliott J, Kahale LA, Sch\u00fcnemann HJ. Living systematic reviews: 4. Living guideline recommendations. J Clin Epidemiol. 2017;91:47\u201353.","journal-title":"J Clin Epidemiol"},{"issue":"7889","key":"1481_CR62","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/d41586-021-03690-1","volume":"600","author":"J Elliott","year":"2021","unstructured":"Elliott J, Lawrence R, Minx JC, Oladapo OT, Ravaud P, Tendal Jeppesen B, et al. Decision makers need constantly updated evidence synthesis. Nature. 2021;600(7889):383\u20135.","journal-title":"Nature"},{"key":"1481_CR63","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jclinepi.2017.08.010","volume":"91","author":"JH Elliott","year":"2017","unstructured":"Elliott JH, Synnot A, Turner T, Simmonds M, Akl EA, McDonald S, et al. Living systematic review: 1. Introduction-the why, what, when, and how. J Clin Epidemiol. 2017;91:23\u201330.","journal-title":"J Clin Epidemiol"},{"key":"1481_CR64","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3379","volume":"370","author":"A Agarwal","year":"2020","unstructured":"Agarwal A, Rochwerg B, Lamontagne F, Siemieniuk RA, Agoritsas T, Askie L, et al. A living WHO guideline on drugs for covid-19. BMJ. 2020;370: m3379.","journal-title":"BMJ"},{"key":"1481_CR65","unstructured":"Australian National COVID-19 Clinical Evidence Taskforce. Australian guidelines for the clinical care of people with COVID-19. https:\/\/files.magicapp.org\/guideline\/ecc67186-0078-4d40-89fb-fc70d3a783af\/published_guideline_6047-50_1.pdf. Accessed 15 Feb 2022."},{"key":"1481_CR66","unstructured":"National Institute for Health and Care Excellence (NICE). COVID-19 rapid guideline: managing COVID-19. https:\/\/files.magicapp.org\/guideline\/bb3004bb-1496-4827-886b-e8a45e5ef4cb\/published_guideline_6040-20_2.pdf. Accessed 22 Feb 2022."},{"key":"1481_CR67","unstructured":"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) in Kooperation mit COVID-19 Evidenz\u00f6kosystem (CEOsys): COVID-19 Evidenzsynthesen und Leitlinienempfehlungen. https:\/\/files.magicapp.org\/guideline\/f0d042d0-ee1d-4282-b165-65942b4b4d5a\/published_guideline_5691-4_0.pdf. Accessed 22 Feb 2022."},{"key":"1481_CR68","unstructured":"World Health Organization. Infection prevention and control in the context of coronavirus disease (COVID-19): living guideline. 2021. https:\/\/files.magicapp.org\/guideline\/32c9b52a-30fb-424a-a68b-fa51c4555125\/published_guideline_5962-1_3.pdf. Accessed 15 Feb 2022."},{"key":"1481_CR69","unstructured":"World Health Organization. Therapeutics and COVID-19: living guideline. 2022. https:\/\/files.magicapp.org\/guideline\/8d102c12-6858-4dfe-ab34-bb8639c158ab\/published_guideline_5999-9_2.pdf. Accessed 15 Feb 2022."},{"key":"1481_CR70","unstructured":"Living Evidence for Diabetes Consortium. Australian evidence-based clinical guidelines for diabetes. https:\/\/diabetessociety.com.au\/20211104%20Guideline-Australian-Evidence-Based-Clinical-Guidelines-for-Diabetes.pdf. Accessed 15 Feb 2022."},{"key":"1481_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108092","volume":"162","author":"N Marx","year":"2020","unstructured":"Marx N, Ryden L, Brosius F, Ceriello A, Cheung M, Cosentino F, et al. Proceedings of the guideline workshop 2019\u2014strategies for the optimization of guideline processes in diabetes, cardiovascular diseases and kidney diseases. Diabetes Res Clin Pract. 2020;162: 108092.","journal-title":"Diabetes Res Clin Pract"},{"key":"1481_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108870","volume":"177","author":"N Marx","year":"2021","unstructured":"Marx N, Ryden L, Brosius F, Ceriello A, Cheung M, Cosentino F, et al. Towards living guidelines on cardiorenal outcomes in diabetes: a pilot project of the Taskforce of the guideline workshop 2020. Diabetes Res Clin Pract. 2021;177: 108870.","journal-title":"Diabetes Res Clin Pract"},{"key":"1481_CR73","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4573","volume":"372","author":"SC Palmer","year":"2021","unstructured":"Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, et al. Sodium\u2013glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021;372: m4573.","journal-title":"BMJ"},{"issue":"6","key":"1481_CR74","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2021","unstructured":"Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2021;43(6):474\u201384.","journal-title":"Eur Heart J"},{"issue":"7","key":"1481_CR75","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s42255-020-0237-2","volume":"2","author":"JS Ayres","year":"2020","unstructured":"Ayres JS. A metabolic handbook for the COVID-19 pandemic. Nat Metab. 2020;2(7):572\u201385.","journal-title":"Nat Metab"},{"issue":"9","key":"1481_CR76","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/S2213-8587(21)00180-7","volume":"9","author":"MN Kosiborod","year":"2021","unstructured":"Kosiborod MN, Esterline R, Furtado RHM, Oscarsson J, Gasparyan SB, Koch GG, et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021;9(9):586\u201394.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1481_CR77","unstructured":"Diabetes UK. Concise advice on inpatient diabetes (COVID:diabetes): front door guidance. 2020. https:\/\/www.diabetes.org.uk\/resources-s3\/public\/2020-04\/COvID_Front_Door_v1.0.pdf. Accessed 22 Feb 2022."},{"issue":"6","key":"1481_CR78","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/S2213-8587(20)30152-2","volume":"8","author":"SR Bornstein","year":"2020","unstructured":"Bornstein SR, Rubino F, Khunti K, Mingrone G, Hopkins D, Birkenfeld AL, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020;8(6):546\u201350.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"1481_CR79","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S2213-8587(21)00244-8","volume":"9","author":"C Steenblock","year":"2021","unstructured":"Steenblock C, Schwarz PEH, Ludwig B, Linkermann A, Zimmet P, Kulebyakin K, et al. COVID-19 and metabolic disease: mechanisms and clinical management. Lancet Diabetes Endocrinol. 2021;9(11):786\u201398.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1481_CR80","unstructured":"World Health Organization. Guideline on evaluation of similar biotheraoeutic products (SBPs). 2013. https:\/\/www.who.int\/biologicals\/publications\/trs\/areas\/biological_therapeutics\/TRS_977_Annex_2.pdf?ua=1. Accessed on 22 Feb 2022."},{"key":"1481_CR81","unstructured":"European Medicines Agency and the European Commission. Biosimilars in the EU\u2014information guide for healthcare professionals. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/leaflet\/biosimilars-eu-information-guide-healthcare-professionals_en.pdf. Accessed 22 Feb 2022."},{"key":"1481_CR82","unstructured":"U.S. Food and Drug Administration. Biological product definitions. https:\/\/www.fda.gov\/files\/drugs\/published\/Biological-Product-Definitions.pdf. Accessed 22 Feb 2022."},{"issue":"Suppl 5","key":"1481_CR83","doi-asserted-by":"publisher","first-page":"v4","DOI":"10.1093\/ndt\/gfl474","volume":"21","author":"M Kuhlmann","year":"2006","unstructured":"Kuhlmann M, Covic A. The protein science of biosimilars. Nephrol Dial Transplant. 2006;21(Suppl 5):v4\u20138.","journal-title":"Nephrol Dial Transplant"},{"issue":"suppl_4","key":"1481_CR84","doi-asserted-by":"publisher","first-page":"iv14","DOI":"10.1093\/rheumatology\/kex278","volume":"56","author":"AG Vulto","year":"2017","unstructured":"Vulto AG, Jaquez OA. The process defines the product: what really matters in biosimilar design and production? Rheumatology. 2017;56(suppl_4):iv14\u201329.","journal-title":"Rheumatology"},{"issue":"3","key":"1481_CR85","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1208\/s12248-016-9882-5","volume":"18","author":"S-C Chow","year":"2016","unstructured":"Chow S-C, Song F, Bai H. Analytical similarity assessment in biosimilar studies. AAPS J. 2016;18(3):670\u20137.","journal-title":"AAPS J"},{"issue":"12","key":"1481_CR86","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1002\/bit.26438","volume":"114","author":"CF Kirchhoff","year":"2017","unstructured":"Kirchhoff CF, Wang XZM, Conlon HD, Anderson S, Ryan AM, Bose A. Biosimilars: key regulatory considerations and similarity assessment tools. Biotechnol Bioeng. 2017;114(12):2696\u2013705.","journal-title":"Biotechnol Bioeng"},{"key":"1481_CR87","unstructured":"U.S. Food and Drug Administration. Guidance document. Scientific considerations in demonstrating biosimilarity to a reference product. 2015. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/scientific-considerations-demonstrating-biosimilarity-reference-product. Accessed 22 Feb 2022."},{"key":"1481_CR88","unstructured":"European Medicines Agency. Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues. 2015. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-non-clinical-clinical-development-similar-biological-medicinal-products-containing_en-0.pdf. Accessed 22 Feb 2022."},{"issue":"9\u201310","key":"1481_CR89","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s10295-019-02216-z","volume":"46","author":"FK Agbogbo","year":"2019","unstructured":"Agbogbo FK, Ecker DM, Farrand A, Han K, Khoury A, Martin A, et al. Current perspectives on biosimilars. J Ind Microbiol Biotechnol. 2019;46(9\u201310):1297\u2013311.","journal-title":"J Ind Microbiol Biotechnol"},{"issue":"4","key":"1481_CR90","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa1203858","volume":"367","author":"HC Gerstein","year":"2012","unstructured":"Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, Origin Trial Investigators, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319\u201328.","journal-title":"N Engl J Med"},{"issue":"8","key":"1481_CR91","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1056\/NEJMoa1615692","volume":"377","author":"SP Marso","year":"2017","unstructured":"Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;377(8):723\u201332.","journal-title":"N Engl J Med"},{"issue":"8","key":"1481_CR92","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.2337\/dc13-0356","volume":"36","author":"DM Nathan","year":"2013","unstructured":"Nathan DM, Buse JB, Kahn SE, Krause-Steinrauf H, Larkin ME, Staten M, et al. Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care. 2013;36(8):2254\u201361.","journal-title":"Diabetes Care"},{"key":"1481_CR93","unstructured":"Nathan DM, Buse JB, Tiktin MA, Younes N. Major results from the glycaemia reduction approaches in diabetes: a comparative effectiveness (GRADE) study. In: Poster presented at: virtual 57th EASD annual meeting; 27 September\u20131 October 2021."},{"issue":"14","key":"1481_CR94","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJM199309303291401","volume":"329","author":"C Diabetes","year":"1993","unstructured":"Diabetes C, Nathan DM, Genuth S, Lachin J, Cleary P, Complications Trial Research G, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977\u201386.","journal-title":"N Engl J Med"},{"issue":"9131","key":"1481_CR95","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837\u201353.","journal-title":"Lancet"},{"issue":"24","key":"1481_CR96","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"HC Gerstein","year":"2008","unstructured":"Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Action to Control Cardiovascular Risk in Diabetes Study G, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545\u201359.","journal-title":"N Engl J Med"},{"issue":"2","key":"1481_CR97","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa0808431","volume":"360","author":"W Duckworth","year":"2009","unstructured":"Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129\u201339.","journal-title":"N Engl J Med"},{"issue":"24","key":"1481_CR98","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","volume":"358","author":"A Patel","year":"2008","unstructured":"Group AC, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560\u201372.","journal-title":"N Engl J Med"},{"issue":"Suppl1","key":"1481_CR99","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.15277\/bjd.2016.070","volume":"16","author":"G Rayman","year":"2016","unstructured":"Rayman G. Glycaemic control, glucose variability and the triangle of diabetes care. Br J Diabetes. 2016;16(Suppl1):S3\u20136.","journal-title":"Br J Diabetes"},{"issue":"1","key":"1481_CR100","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1753-0407.2009.00009.x","volume":"1","author":"EJ Gallagher","year":"2009","unstructured":"Gallagher EJ, Le Roith D, Bloomgarden Z. Review of hemoglobin A(1c) in the management of diabetes. J Diabetes. 2009;1(1):9\u201317.","journal-title":"J Diabetes"},{"issue":"1","key":"1481_CR101","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1136\/jclinpath-2017-204755","volume":"72","author":"L Campbell","year":"2019","unstructured":"Campbell L, Pepper T, Shipman K. HbA1c: a review of non-glycaemic variables. J Clin Pathol. 2019;72(1):12\u20139.","journal-title":"J Clin Pathol"},{"issue":"3","key":"1481_CR102","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1177\/1932296818812062","volume":"13","author":"G Freckmann","year":"2019","unstructured":"Freckmann G, Pleus S, Grady M, Setford S, Levy B. Measures of accuracy for continuous glucose monitoring and blood glucose monitoring devices. J Diabetes Sci Technol. 2019;13(3):575\u201383.","journal-title":"J Diabetes Sci Technol"},{"key":"1481_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108502","volume":"170","author":"RJ Galindo","year":"2020","unstructured":"Galindo RJ, Aleppo G. Continuous glucose monitoring: the achievement of 100 years of innovation in diabetes technology. Diabetes Res Clin Pract. 2020;170: 108502.","journal-title":"Diabetes Res Clin Pract"},{"key":"1481_CR104","doi-asserted-by":"crossref","unstructured":"Weinstock RS, Aleppo G, Bailey TS, Bergenstal RM, Fisher WA, Greenwood DA, et al. The role of blood glucose monitoring in diabetes management American Diabetes Association \u00a9 2020 by American Diabetes Association all rights reserved none of the contents may be reproduced without the written permission of the American Diabetes Association Arlington (VA); 2020.","DOI":"10.2337\/db2020-31"},{"issue":"8","key":"1481_CR105","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.2337\/dci19-0028","volume":"42","author":"T Battelino","year":"2019","unstructured":"Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593\u2013603.","journal-title":"Diabetes Care"},{"issue":"3","key":"1481_CR106","doi-asserted-by":"publisher","first-page":"400","DOI":"10.2337\/dc18-1444","volume":"42","author":"RW Beck","year":"2019","unstructured":"Beck RW, Bergenstal RM, Riddlesworth TD, Kollman C, Li Z, Brown AS, et al. Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care. 2019;42(3):400\u20135.","journal-title":"Diabetes Care"},{"issue":"11","key":"1481_CR107","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.2337\/dc18-1131","volume":"41","author":"J Lu","year":"2018","unstructured":"Lu J, Ma X, Zhou J, Zhang L, Mo Y, Ying L, et al. Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes. Diabetes Care. 2018;41(11):2370\u20136.","journal-title":"Diabetes Care"},{"issue":"1","key":"1481_CR108","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2019-000991","volume":"8","author":"L Mayeda","year":"2020","unstructured":"Mayeda L, Katz R, Ahmad I, Bansal N, Batacchi Z, Hirsch IB, et al. Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease. BMJ Open Diabetes Res Care. 2020;8(1): e000991.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"2","key":"1481_CR109","doi-asserted-by":"publisher","first-page":"549","DOI":"10.2337\/dc20-1862","volume":"44","author":"J Lu","year":"2021","unstructured":"Lu J, Wang C, Shen Y, Chen L, Zhang L, Cai J, et al. Time in range in relation to all-cause and cardiovascular mortality in patients with type 2 diabetes: a prospective cohort study. Diabetes Care. 2021;44(2):549\u201355.","journal-title":"Diabetes Care"},{"issue":"Supplement_1","key":"1481_CR110","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.2337\/dc21-S006","volume":"44","author":"American Diabetes Association","year":"2020","unstructured":"American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes\u20142021. Diabetes Care. 2020;44(Supplement_1):S73\u201384.","journal-title":"Diabetes Care"},{"key":"1481_CR111","unstructured":"U.S. Food and Drug Administration. FDA approves first continuous glucose monitoring system with a fully implantable glucose sensor and compatible mobile app for adults with diabetes. 2018. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-continuous-glucose-monitoring-system-fully-implantable-glucose-sensor-and. Accessed 22 Feb 2022."},{"key":"1481_CR112","unstructured":"U.S. Food and Drug Administration. Enforcement policy for non-invasive remote monitoring devices used to support patient monitoring during the coronavirus disease 2019 (COVID-19) public health emergency (revised). 2020. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/enforcement-policy-non-invasive-remote-monitoring-devices-used-support-patient-monitoring-during. Accessed 22 Feb 2022."}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-022-01481-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-022-01481-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-022-01481-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T03:29:23Z","timestamp":1675222163000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-022-01481-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,8]]},"references-count":112,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1481"],"URL":"https:\/\/doi.org\/10.1186\/s12933-022-01481-0","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,8]]},"assertion":[{"value":"8 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The following\u00a0authors declare competing interests:\u00a0OS (Oliver Schnell): AstraZeneca, Bayer, Boehringer Ingelheim, Gr\u00fcnethal, Lilly, MSD, Mundipharma, Novo Nordisk, Roche, Sanofi, W\u00f6rwag.\u00a0RB (Richard Bergenstal): Richard M. Bergenstal, MD has received research support, acted as a consultant, or been on the scientific advisory board for Abbott Diabetes Care, Ascensia, Bigfoot Biomedical, CeQur, DexCom, Eli Lilly, Hygieia, Insulet, Medtronic, Novo Nordisk, Onduo, Sanofi, United Healthcare and Zealand. Dr. Bergenstal\u2019s employer, non-profit HealthPartners Institute, contracts for his services and he receives no personal income for these services. MB (Matthias Bl\u00fcher): Honoraria as a consultant and speaker from Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Lilly, Novo Nordisk, Novartis, Pfizer, and Sanofi. MB (Michael B\u00f6hm): Research support (DFG, SFB-TTR 219, S-01): Deutsche Forschungsgemeinschaft; Speakers honoraria: Abbott, Amgen, Astra Zeneca, Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Cytokinetics, Edwards, Medtronic, Novartis, Servier, Vifor; Advisory board: Amgen, Bayer, Boehringer Ingelheim, Cytokinetics, Edwards, Medtronic, Novartis, Pfizer, ReCor, Servier, Vifor. HJLH (Hiddo Heerspink): Payments to my institution: AstraZeneca, Boehringer Ingelheim, Janssen, Novo Nordisk; Payments for consultancy to my institution: Dr. L Heerspink reports consulting fees from AstraZeneca, Abbvie, Boehringer Ingelheim, CSL Behring, Bayer, Chinook, Dimerix, Gilead, Goldfinch, Merck, NovoNordisk, Janssen, Travere Pharmaceuticals; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Institution: AstraZeneca. BI (Baruch Itzhak): Advisory Board, Consultancy, Lectures: Novo Nordisk, Sanofi, Eli Lilly, Bayer, AstraZeneca, Boehringer Ingelheim, Merck Sharp & Dohme, Pfizer, Roche Diagnostic, and Medtronic. MK (Mikhail Kosiborod): Research Grant: Astra Zeneca, Boehringer Ingelheim; Consultant\/Advisory Board: Alnylam, Amgen, Applied Therapeutics, Astra Zeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Eli Lilly, Esperion Therapeutics, Janssen, Lexicon, Merck (Diabetes and Cardiovascular), Novo Nordisk, Pharmacosmos, Sanofi, Vifor Pharma; Other Research Support: Astra Zeneca; Honorarium: Astra Zeneca, Boehringer Ingelheim, Novo Nordisk. NM (Nikolaus Marx): Speaker: Abbott, AstraZeneca, Bayer, Boehringer Ingelheim \/ Lilly, Bristol-Myers Squibb, Novo Nordisk, Sanofi Aventis; Consultant: AstraZeneca, Bayer, Boehringer Ingelheim \/ Lilly, MSD, Novo Nordisk; Grant support: Boehringer Ingelheim, MSD. PR (Peter Rossing): Consultancy and\/or speaking fees (to his institution) from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Gilead, MSD, Mundipharma, Novo Nordisk, Vifor, and Sanofi Aventis; Research grants from AstraZeneca and Novo Nordisk. LR (Lars Ryd\u00e9n): The authors declare that they have no competing interests. PMSD (Petra-Maria Schumm-Draeger): Grant to institution; Consulting fees: AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Sanofi, Lilly; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Boehringer Ingelheim, AstraZeneca, Lilly, Novo Nordisk, Sanofi, Hexal, AristoPharma, MSD, Berlin Chemie, Merck, GSK, BMS; Participation on a Data Safety Monitoring Board or Advisory Board: Sanofi, Novo Nordisk, Boehringer Ingelheim, Merck, BMS, AstraZeneca, GSK; Executive Board: European Federation of Internal Medicine; Leadership and executive board: German Society of Internal Medicine; Executive board: Professional German Society of Internal Medicine. POV (Per Olav Vandvik): CEO of MAGIC Evidence Ecosystem Foundation, responsible for MAGICapp as a platform to produce, publish and dynamically update guidelines. MAGIC supports WHO, NICE and other organisations in living guidelines. CW (Christoph Wanner): Grants to institution: Idorsia, Sanofi and Boehringer Ingelheim; Consulting fees: AstraZeneca, Boehringer Ingelheim, Idorsia, Bayer, GILEAD, GSK, and MSD; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Boehringer Ingelheim, AstraZeneca, FMC, Chiesi, Lilly, and Vifor; Participation on Data Safety Monitoring Board or Advisory Board: Sanofi and the Australasian Kidney Trials Network; Leadership: European Renal Association. TB (Tadej Battelino), FB (Frank Brosius), RDC (Richard D. Carr), AC (Antonio Ceriello), TF (Thomas Forst), FG (Francesco Giorgino), BC (Bruno Guerci), LJ (Linong Ji),\u00a0NL (Neboj\u0161a Lali\u0107), ML (Michael Lehrke), MN (Michael Nauck), HWR (Helena W. Rodbard), GMCR (Giuseppe M.C. Rosano), FS (Francesca Santilli), TV (Tina Vilsb\u00f8ll), CW (Carol Wysham), ES (Eberhard Standl) did not declare any competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}